The company said Thursday that the layoffs represent over 25 percent of its global work force. The job cuts are to occur over the next two years, with most of them expected in 2018.
In a letter to employees, Chief Executive Kare Schultz says the restructuring is “crucial to restoring our financial security and stabilizing our business.”
Teva’s bottom line has been hit by the expiration of patents on Copaxone, a drug for multiple sclerosis; pricing pressure on its core generics business and a $35 billion debt load taken on in its acquisition of the generics business of Allergan.
Teva’s stock has skidded nearly 60 percent this year.